Orchestrate continued success

in KIT+ GIST with GLIVEC1

Recently Resected Patient
Meet Karen
Adjuvant Patient
Meet Chen
Newly Metastatic Patient
Meet Omar
Metastatic Patient With Progression

Models are used for ilustrative purposes only throughout the site. Patient quotes are intended for guidance only and do not reflect actual patient testimonials.

Recently
Resected
KIT+ GIST
Newly
Metastatic
KIT+ GIST
Adjuvant
KIT+ GIST
Metastatic
KIT+ GIST
With Progression

Models are used for illustrative purposes only throughout the site. Patient quotes are intended for guidance only and do not reflect actual patient testimonials.

GLIVEC® (imatinib) is indicated for:

  • The treatment of adult patients with KIT (CD117)-positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST)
  • The adjuvant treatment of adult patients who are at significant risk of relapse following resection of KIT (CD117)-positive GIST. Patients who have a low or very low risk of recurrence should not receive adjuvant treatment

Reference: 1. Glivec® (imatinib) summary of product characteristics. West Sussex, UK: Novartis Europharm Limited; 2016.